Boston Scientific Enters into a Definitive Agreement to Acquire SoniVie for $600M

Shots: Boston Scientific entered into a definitive agreement to acquire SoniVie Ltd. to expand its interventional cardiology therapies offerings Currently, the company holds an equity stake of approx. 10%, and for the remaining 90% stake, the company will pay approx. $360M upfront and up to $180M regulatory milestones; for 100% stake, the amount sums…

ByRidhi RastogiMarch 4, 2025

NEWS

BridgeBio Oncology Therapeutics (BBOT) Enters into Business Combination Agreement with Helix Acquisition Corp. II to Develop RAS and PI3Kα-Targeting Drugs

Shots: BBOT will reverse merge with Helix in a SPAC transaction, where combined entity - "BBOT” will be listed on Nasdaq; closing expected in Q3’25 Upon closing, BBOT will have ~$550M cash (pre-transaction) incl. $100M in existing cash, $196M from Helix’s trust & $260M from PIPE financing. At $10.36/share, the combined entity's implied pro…

ByRidhi RastogiMarch 3, 2025

NEWS

Teleflex Enters a Definitive Agreement to Acquire BIOTRONIK’s Vascular Intervention Business for ~$797.7M (€760M)

Shots: Teleflex to acquire BIOTRONIK's vascular intervention business for ~$797.7M (€760M) in cash, subject to adjustments. Closing expecting in Q3’25 Acquisition will expand Teleflex’s interventional portfolio with coronary products like Pantera Lux Catheter, PK Papyrus Covered Stent & Orsiro Stent, plus peripheral product like Passeo-18 Lux Catheter, Dynetic-35 Stent, & Pulsar-18 T3 4F Stent,…

ByRidhi RastogiFebruary 28, 2025

NEWS

Thermo Fisher Scientific to Acquire Solventum’s Purification & Filtration Business for ~$4.1B

Shots: Thermo Fisher has entered into definitive agreement with Solventum to acquire its purification & filtration business for ~$4.1B in cash, adding value to its upstream and downstream biologics development & manufacturing Transaction is expected to close by the end of 2025, pending regulatory approval & customary closing conditions Solventum's purification and filtration unit…

ByRidhi RastogiFebruary 26, 2025

NEWS

Carlyle & SK Capital to Acquire Bluebird Bio

Shots: Carlyle & SK Capital have entered into definitive agreement to acquire Bluebird Bio for $3/share in cash, delisting it from public market. Acquisition will fund Bluebird’s commercial delivery of gene therapies for SCD, β-thalassemia, & cerebral adrenoleukodystrophy, with closing expected in H1’25 As per the deal, Bluebird stockholders will get $3/share & contingent…

ByRidhi RastogiFebruary 24, 2025

NEWS

AstraZeneca Purchases FibroGen China for ~$160M

Shots: AstraZeneca has purchased FibroGen’s China subsidiary for ~$160M ($85M enterprise value + ~$75M net cash) with closing expected in mid-2025, obtaining full rights to roxadustat in China The sale allows FibroGen to repay its Morgan Stanley Tactical Value loan & extend its cash runway to 2027 for advancing FG-3246 in P-II trial for…

ByRidhi RastogiFebruary 21, 2025

NEWS

Cosette Pharmaceuticals to Acquire Mayne Pharma for ~$430M

Shots: Cosette Pharmaceuticals to acquire Mayne Pharma Group for ~$430M, with shareholders receiving $4.71/share. Closing expected in Q2’25 Acquisition will strengthen Cosette’s dermatology & women’s health business, adding 12 patent-protected products incl. Vyleesi, Intrarosa, Nextstellis, Annovera, Bijuva, Imvexxy, & Rhofade along with multiple pipeline candidates in its product line upon closing The combined…

ByRidhi RastogiFebruary 21, 2025

NEWS

Bain Capital to Acquire Mitsubishi Tanabe Pharma for ~$3.3B

Shots: Bain Capital has signed to acquire Mitsubishi Tanabe Pharma in a carve-out deal from Mitsubishi Chemical Group at ~510 billion JPY (3.3 billion USD), is led by Bain Capital’s Private Equity teams in Asia, North America, and its Life Sciences team. The transaction is expected to close in Q3’25, pending regulatory approval, shareholder…

ByRidhi RastogiFebruary 7, 2025

NEWS

Alumis Signs a Definitive Merger Agreement with ACELYRIN to Develop Novel Therapies for Immune-mediated Diseases

Shots: Alumis & ACELYRIN have entered into a definitive agreement to merge, with ACELYRIN stockholders receiving 0.4274 Alumis shares/share, owning 45% of the combined entity - "Alumis"; closing expected in Q2’25 As of Dec 31, 2024, Alumis & ACELYRIN had ~$289M & ~$448M in cash as well as investments, respectively, with a pro forma…

ByRidhi RastogiFebruary 7, 2025

NEWS

Relmada Therapeutics Acquires Sepranolone from Asarina Pharma for ~$3.12M

Shots: Relmada acquired the Sepranolone from Asarina for $3.12M via an asset purchase agreement to develop it as a potential treatment for Tourette syndrome (TS) & other compulsive disorders Sepranolone (10mg, BIW, SC) is a GABAA-modulating steroid antagonist that is being investigated in a P-IIa trial, assessing it with SoC vs SoC alone in…

ByRidhi RastogiFebruary 7, 2025

Boston Scientific Enters into a Definitive Agreement to Acquire SoniVie for $600M

BridgeBio Oncology Therapeutics (BBOT) Enters into Business Combination Agreement with Helix Acquisition Corp. II to Develop RAS and PI3Kα-Targeting Drugs

Teleflex Enters a Definitive Agreement to Acquire BIOTRONIK’s Vascular Intervention Business for ~$797.7M (€760M)

Thermo Fisher Scientific to Acquire Solventum’s Purification & Filtration Business for ~$4.1B

Carlyle & SK Capital to Acquire Bluebird Bio

AstraZeneca Purchases FibroGen China for ~$160M

Cosette Pharmaceuticals to Acquire Mayne Pharma for ~$430M

Bain Capital to Acquire Mitsubishi Tanabe Pharma for ~$3.3B

Alumis Signs a Definitive Merger Agreement with ACELYRIN to Develop Novel Therapies for Immune-mediated Diseases

Relmada Therapeutics Acquires Sepranolone from Asarina Pharma for ~$3.12M

Contact US

FOLLOW US